Journal
PROTEOMICS CLINICAL APPLICATIONS
Volume 12, Issue 3, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201700120
Keywords
activin type II receptors (ActRII); affinity purification; doping; LC-IM-HRMS; therapeutic antibody
Funding
- Novartis
- Federal Ministry of the Interior of the Federal Republic of Germany
- Manfred-Donike Institute for Doping Analysis (Cologne, Germany)
Ask authors/readers for more resources
PurposeInhibitors of the ActRII signaling pathways represent promising therapeutics for the treatment of muscular diseases, but also pose risks as performance-enhancing agents in sports. Bimagrumab is a human anti-ActRII antibody which was found to increase muscle mass and function by blocking ActRII signaling. As it has considerable potential for being misused as doping agent in sports, the aim of this study was to develop a mass spectrometric detection assay for doping control serum samples. Experimental designWithin this study, a detection method for Bimagrumab in human serum was developed, which combines ammonium sulfate precipitation and affinity purification with proteolytic digestion and LC-HRMS. To facilitate the unambiguous identification of the diagnostic peptides, an orthogonal IM separation was additionally performed. ResultsThe assay was successfully validated and the analysis of clinical samples demonstrated its fitness for purpose for an application in routine doping control analysis. Conclusions and clinical relevanceAlthough no myostatin inhibitors have obtained clinical approval yet, the proactive development of detection methods for emerging doping agents represents a key aspect of preventive doping research. The presented approach will expand the range of available tests for novel protein therapeutics and can readily be modified to include further target analytes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available